• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Goodbye Michel!

Rest of EC is next. Good riddance. Rachid and AA next?
"New" CEO either interim BOD member or somoeone to sell off Biogen

At times like these, you need a steady hand at the helm. One who brings cheer as the buzzword clown and lacks substance.

Chirfi for ceo will be the next movement.

Let the circus continue
 




Next CEO of Biogen needs to be Paul Clancy. He’s the only one with the respect and knowledge of Biogen current crapstorm to accomplish the task. He will meet the ethical piece as he’s known to be an honorable man, and second he’s damn smart.
My vote, Paul Clancy!!!

Face pubes Sandrock is rested and ready!
 




So many brainless internal choices. Why go outside and will someone external with a brain take the role as it will take at least 3 years to just detoxify the place and get some talent. Unless you want to accept the mantle of toilet company ceo. But hey at 15M + per year and a golden parachute, im game.
 




So many brainless internal choices. Why go outside and will someone external with a brain take the role as it will take at least 3 years to just detoxify the place and get some talent. Unless you want to accept the mantle of toilet company ceo. But hey at 15M + per year and a golden parachute, im game.

next CEO’s job is to put lipstick on the pig and sell it for parts. Unfortunately it’s mostly shriveled up.
 












Betting Clancy is on the new england coast in shorts and a bankers shirt. Smart enough i think not to be interested in working on a company in such disrepair and still sinking somehow.
 




























Ron Cohen of Acorda (makers of Ampyra/Fampyra) has deep experience in perserving executive compensation while core products lose exclusively and botching commercialization efforts of newly approved FDA drugs, destroying equity value. Perhaps he would be a good candidate for CEO of Biogen.
 








Ron Cohen of Acorda (makers of Ampyra/Fampyra) has deep experience in perserving executive compensation while core products lose exclusively and botching commercialization efforts of newly approved FDA drugs, destroying equity value. Perhaps he would be a good candidate for CEO of Biogen.

You had me at executive compensation.
 








I like the idea of pivoting the 'never' trolling, but I am not sure if this is it. Three words is the sweet spot maybe? I don't know what the answer is, but I will know it when I see it. I love your work and am excited to see what you come up with.

I agree.

The new CEO troll just felt kind of "forced" and didn't quite hit the same as the original.